Mark H Stoler

发表

The ATHENA human papillomavirus study: design, methods, and baseline results.

Thomas C Wright, Mark H Stoler, Catherine M Behrens, 2012, American journal of obstetrics and gynecology.

The Quality of Her-2/Neu Predictive Immunohistochemistry: Something FISHy?

Raymond R Tubbs, Mark H Stoler, M. Stoler, 2000, Modern Pathology.

A mobile-phone based high-resolution microendoscope to image cervical precancer

Rebecca Richards-Kortum, Timothy Quang, Mark H Stoler, 2019, PloS one.

The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology.

David C Wilbur, Mark H Stoler, J. T. Cox, 2012, Journal of lower genital tract disease.

Advances in Cervical Screening Technology

Mark H Stoler, M. Stoler, 2000, Modern Pathology.

Interlaboratory variation in the performance of liquid‐based cytology: Insights from the ATHENA trial

Thomas C Wright, Mark H Stoler, Catherine M Behrens, 2014, International journal of cancer.

New Bethesda terminology and evidence-based management guidelines for cervical cytology findings.

Mark H Stoler, M. Stoler, 2002, JAMA.

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.

Thomas C Wright, Mark H Stoler, Catherine M Behrens, 2011, The Lancet. Oncology.

The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report.

Diane Solomon, Mark Schiffman, Mark H Stoler, 2007, American journal of clinical pathology.

Polymorphism at Codon 72 of p53 Is Not Associated with Cervical Cancer Risk

Mark H Stoler, M. Stoler, James C Boyd, 2000, Modern Pathology.

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

Cosette M Wheeler, Diane M Harper, Mark H Stoler, 2005, The Lancet. Oncology.